Key result
Transfemoral access shows no difference in 30-day mortality or major events vs upper extremity access in TAMBE.
Why the study?
Early experience with the Thoracoabdominal Multibranch Endoprosthesis device relied on routine upper extremity access, while total transfemoral approaches have emerged to minimise aortic arch manipulations and neurological complications, motivating a comparison of outcomes between these access strategies.
Does total transfemoral access improve thirty-day mortality and major adverse events compared to upper extremity access in patients undergoing Thoracoabdominal Multibranch Endoprosthesis (TAMBE) implantation?
Cohort (n=100)
No
Does total transfemoral access improve thirty-day mortality and major adverse events compared to upper extremity access in patients undergoing Thoracoabdominal Multibranch Endoprosthesis (TAMBE) implantation?
Answers are grounded in this paper and cite their sources.
In this single-centre cohort, total transfemoral access for TAMBE implantation yielded similar 30-day mortality, major adverse events, and technical success compared with routine upper extremity access.
OBJECTIVE: Early experience with the Thoracoabdominal Multibranch Endoprosthesis (TAMBE) device relied on routine upper extremity access (UEA), but total transfemoral approaches have emerged to minimise aortic arch manipulations and the risk of neurological complications. The aim of this study was to evaluate outcomes following total transfemoral access (TFA) vs. UEA for TAMBE implantation. METHODS: A retrospective review of consecutive patients undergoing TAMBE implantation at a single centre between April 2020 and January 2026 was performed. Patients were stratified by access strategy into TFA and UEA. The primary outcomes were thirty day mortality and major adverse events (MAEs). RESULTS: One hundred patients underwent TAMBE implantation during the study period, of whom 32 underwent TFA and 68 UEA. The majority of aneurysms treated were thoraco-abdominal aortic aneurysms (61%), and 45% of patients had a prior endovascular intervention with no significant difference between groups (all p > .050). Mean operative time (232.8 ± 92.4 minutes vs. 250.8 ± 77.3 minutes; p = .18) and fluoroscopy time (59.2 ± 28.4 minutes vs. 48.3 ± 21.6 minutes; p = .066) were not statistically different between groups. Technical success was 91% in the TFA group compared with 99% in the UEA group (p = .095). Thirty day mortality (3% vs. 3%; p = 1.0) and MAEs (16% vs. 13%; p = .76) were not statistically different between TFA and UEA groups. Spinal cord ischaemia rates were 16% for the TFA group and 7% for the UEA group (p = .16), with most cases mild and resolved by discharge (80%). No stroke events occurred in either group. At 6 months, overall branch patency was 92% (78 of 85 branches from 22 patients), including 83% (15 of 18 branches from five patients) in the TFA group and 94% (63 of 67 branches from 17 patients) in the UEA group (p = .16). CONCLUSION: In this single centre experience, total transfemoral TAMBE implantation was performed in selected patients, and no statistically significant differences were detected in thirty day mortality, MAEs, and technical success between access strategies. Larger studies are needed to determine whether clinically meaningful differences exist.
No takes yet. Share an insight, caveat, or question.
Tackett et al. (2026) conducted a cohort in Thoracoabdominal aortic aneurysm and other aortic aneurysms requiring TAMBE implantation (n=100). Total transfemoral access (TFA) for TAMBE implantation vs. Upper extremity access (UEA) for TAMBE implantation was evaluated on Thirty day mortality and major adverse events (MAEs) (p=0.76). Total transfemoral access for TAMBE implantation showed no significant differences vs upper extremity access in 30-day mortality or major adverse events.
Synapse has enriched 10 related papers. Consider them for comparative context: